Bladder cancer falls in the seventh place in male incidence of cancer and increases yearly.1 Even though transurethral resection has been served as the standard treatment, recurrence and metastasis are often seen in clinic.2 The commonest way to prevent recurrence and progression is to supplement transurethral resection with intravesical chemotherapy or immunosuppressive agents.3, 4 No substantial progress over the past 3 decades has been reported in clinical administration for bladder cancer except FDA‐approved PD‐L1 treatment in 2016.5 Here, CD274 is linked to urinary bladder carcinoma.